Linfoma de Hodgkin

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.

2. Glaser SL, Jarrett RF. The epidemiology of Hodgkin’s disease. Baillieres Clin Haematol. 1996;9(3):401-416.

3. Grufferman S, Cole P, Smith PG, Lukes RJ. Hodgkin’s disease in siblings. N Engl J Med. 1977;296(5):248-250.

4. Lynch HT, Marcus JN, Lynch JF. Genetics of Hodgkin’s and non-Hodgkin’s lymphoma: a review. Cancer Invest. 1992;10(3):247-256.

5. Mack TM, CozenW, Shibata DK, et al. Concordance for Hodgkin’s disease in identical twins suggesting  genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995;332(7):413-418.

6. Horwitz M, Wiernik PH. Pseudoautosomal linkage of Hodgkin disease. Am J Hum Genet. 1999;65(5):1413-1422.

7. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathol. 1987;129(1):86-91.

8. Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin’s lymphoma and other lymphoid neoplasms. Int J Cancer. 1999;83(4):481-485.

9. Andrieu JM, Roithmann S, Tourani JM, et al. Hodgkin’s disease during HIV1 infection: the French registry experience. Ann Oncol. 1993;4(8):635-641.

10. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13(7):1758-1767.

11. Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin’s disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer. 2000;82(5):1117-1121.

12. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.

13. Stein H, Delsol G, Pileri SA. Hodgkin Lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours: Pathology & Genetics; Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France:

IARC Press; 2001:237-253.

14. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.

15. Ekstrand BC, Horning SJ. Hodgkin’s disease. Blood Rev. 2002; 16(2):111-117.

16. Pinkus GS, Said JW. Hodgkin’s disease, lymphocyte predominance type, nodulardfurther evidence for a B cell derivation: L & H variants of Reed-Sternberg cells express L26, a pan B cell marker. Am J Pathol. 1988;133(2):211-217.

17. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17(3):776-783.

18. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86(3):266-273.

19. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease: the EORTC Lymphoma Group controlled clinical trials; 1964-1987. Blood.1989;73(1):47-56.

20. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc H Educ Program. 2003:225-247.

21. Hasenclever D, Diehl V; International Prognostic Factors Project on Advanced Hodgkin’s Disease. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506-1514.

22. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429-433.

23. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10(10):1181-1184.

24. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107(1):52-59.

25. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-3752.

26. Brusamolino E, Lazzarino M, Orlandi E, et al. Early-stage Hodgkin’s disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol. 1994; 5(suppl):2101-2106.

27. Meyer RM, Gospodarowicz MK, Connors JM, et al; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399-408.

28. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835-2841.

29. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640-652.

30. Radford J, Illidge T, Counsell N, et al. Results of a trial of PETdirected therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598-1607.

31. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601-3608.

32. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-4206.

33. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907-913.

34. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-1833.

35. André MPE, Reman O, Federico M, et al. Interim analysis of the randomized Eortc/Lysa/Fil Intergroup H10 trial on early PETscan driven treatment adaptation in stage I/II Hodgkin lymphoma [abstract]. Blood. 2012;120(21):549.

36. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10(2):210-218.

37. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.

38. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol. 1996;14(5):1421-1430.

39. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin’s disease with chemotherapydcomparison of MOPP/ ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group [published correction appears in J Clin Oncol. 1997;15(7):2762]. J Clin Oncol. 1997;15(4):1638-1645.

40. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21(4):607-614.

41. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for [1]bulky or advanced-stage Hodgkin’s disease: a preliminary